Open AccessThe Complementarity Effect for Cdc25 Phosphatase Inhibitors
Author(s) -
Wassila Soufi,
M.S. Merad,
Faïza Boukli,
Saïd Ghalem
Publication year - 2011
Publication title -
advances in molecular imaging
Language(s) - English
Resource type - Journals
eISSN - 2161-6752
pISSN - 2161-6728
DOI - 10.4236/ami.2011.12003
Subject(s) - cdc25 , phosphatase , cdc25a , cell cycle , cancer research , biology , in vivo , mitosis , cancer , cell cycle checkpoint , microbiology and biotechnology , phosphorylation , genetics , cyclin dependent kinase 1
Cdc25 phosphatase have been regarded as attractive drug targets for anticancer therapies due to the correlation of their over expression with a wide variety of cancers. They are key regulators of cell cycle progression and play a central role in the checkpoint response to DNA damage. The role of Cdc25 s in cancer has become increasingly evident in recent years. More than 20 studies of patient samples are from diverse cancers show significant overexpression of Cdc25 with frequent correlation to clinical outcome. Recent screening and design efforts have yielded novel classes of inhibitors that show specificity for the Cdc25 s over other phosphatases and cause cell cycle arrest in vivo. Until now, quinone derivatives are among the most efficient inhibitors of Cdc25 phosphatase activity. Our research objective is to study the inhibition of the phosphathase Cdc25 through the molecular modeling methods